CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 80 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $80,000 | -81.2% | 44,601 | -12.0% | 0.04% | -79.1% |
Q2 2020 | $425,000 | +13.6% | 50,694 | -28.9% | 0.20% | +30.5% |
Q1 2020 | $374,000 | -16.1% | 71,343 | -12.7% | 0.15% | +111.0% |
Q4 2019 | $446,000 | +147.8% | 81,751 | +121.7% | 0.07% | +102.8% |
Q3 2019 | $180,000 | -33.3% | 36,881 | -5.3% | 0.04% | -36.8% |
Q2 2019 | $270,000 | -4.3% | 38,935 | -4.2% | 0.06% | -90.5% |
Q1 2019 | $282,000 | +4.8% | 40,628 | -12.0% | 0.60% | +1204.3% |
Q4 2018 | $269,000 | -54.0% | 46,147 | -40.4% | 0.05% | -23.3% |
Q3 2018 | $585,000 | -12.8% | 77,428 | -41.7% | 0.06% | -89.9% |
Q2 2018 | $671,000 | +7.4% | 132,890 | +29.7% | 0.59% | +9.4% |
Q1 2018 | $625,000 | +85.5% | 102,493 | +116.1% | 0.54% | +28.1% |
Q4 2017 | $337,000 | -15.8% | 47,426 | -15.2% | 0.42% | +683.3% |
Q3 2017 | $400,000 | +25.0% | 55,909 | +10.1% | 0.05% | +12.5% |
Q2 2017 | $320,000 | +19.4% | 50,795 | +56.1% | 0.05% | 0.0% |
Q1 2017 | $268,000 | +7.6% | 32,545 | +10.6% | 0.05% | -35.1% |
Q4 2016 | $249,000 | – | 29,425 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 5,045,870 | $42,335,000 | 24.44% |
MANGROVE PARTNERS IM, LLC | 552,200 | $4,633,000 | 1.13% |
ETF MANAGERS GROUP, LLC | 3,707,912 | $31,109,000 | 1.10% |
Ikarian Capital, LLC | 1,350,000 | $11,327,000 | 0.90% |
GENERAL AMERICAN INVESTORS CO INC | 712,400 | $5,977,000 | 0.76% |
AdvisorShares Investments LLC | 189,814 | $1,593,000 | 0.68% |
Ikarian Capital, LLC | 1,000,000 | $8,390,000 | 0.67% |
Granite Point Capital Management, L.P. | 1,123,600 | $9,427,000 | 0.48% |
Carmignac Gestion | 3,773,440 | $31,659,000 | 0.44% |
Omnia Family Wealth, LLC | 32,356 | $271,467,000 | 0.27% |